|
|
索托拉西布市场分析报告
|
Lumakras Drug Clinical Insight & Sales Forecast 2026
... Market Opportunity (US$ Million) Pharmacokinetics of Lumakras (Sotorasib) Dosage, Patent & Price Analysis Lumakras ... -small cell lung cancer. Lumakras (Sotorasib) is first KRAS inhibitor developed by Amgen ...
Global KRAS Inhibitors Market, Drug Price, Sales, & Clinical Trials Insight 2029
... first ever KRAS inhibitor, Lumakras (Sotorasib) developed by Amgen in 2021 for treatment ... AURKA Inhibitor VIC-1911 and Sotorasib a G12C inhibitor for the treatment ... -1911 as monotherapy and in combination with Sotorasib is being performed at Yale Cancer Centre ...
Lung Cancer Therapy Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Therapy Type (Noninvasive and Minimally Invasive), Indication (Non-Small Cell Lung Cancer and Small Cell Lung Cancer), End User (Hospitals, Oncology Clinics, Research Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
... and Drug Administration approved Lumakras (sotorasib), the first treatment for adult ... 2021, the US FDA approved Lumakras (sotorasib) as the first targeted therapy for ...
Global KRAS Inhibitors Market & Clinical Trials Future Outlook 2030
... . The first KRAS inhibitor, Lumakras (sotorasib), developed by Amgen in May 2021, and ... as, a phase 3 trial, CodeBreaK 200, is evaluating sotorasib in combination with chemotherapy (docetaxel or pemetrexed ...
Global KRAS Inhibitors Market, Drug Sales, Patent, Price & Clinical Trials Insight 2030
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location. Global KRAS Inhibitors Market, Drug Sales, Patent, Price & Clinical Trials Insight 2030 Report Findings & Highlights: Research Methodology Global ...
Global KRAS Inhibitors Market Opportunity & Clinical Trials Outlook 2025
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location. "Global KRAS Inhibitors Market Opportunity & Clinical Trials Outlook 2025" Report Highlights: KRAS Inhibitors Market Opportunity: > USD 1 Billion ...
ACE/ARB Inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 24 Hours DelveInsight’s, “ACE/ARB Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in ACE/ARB Inhibitors pipeline landscape. It covers ...
MTORC1 protein inhibitors - Pipeline Insight, 2022
... Ingelheim REVOLUTION Medicines Key Products Sotorasib Sapanisertib Research programme: mTOR inhibitors ...
Metastatic Colorectal cancer - Pipeline Insight, 2022
... Karyopharm Therapeutics Key Products Trilaciclib Sotorasib QL 1203 Lenvatinib Olaparib MRTX 849 ...
Cancer Therapy - Market Insights, Competitive Landscape and Market Forecast–2027
... 2021, Health Canada approved LUMAKRAS™ (sotorasib) – the first and only targeted ...
Oncology Drugs- Market Insights, Competitive Landscape and Market Forecast–2027
... 2021, Health Canada approved LUMAKRAS™ (sotorasib) – the first and only targeted ...
KRAS Market by Target Indication (Acute Myeloid Leukemia, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Phelan-McDermid Syndrome, and Skin Cancer), Type of Molecule (Biologic and Small Molecule), Type of Therapy (Monotherapy and Combination Therapy), and Route of Administration (Intravenous, Intramuscular, Intradermal, Intraocular, Intraperitoneal, Oral, and Subcutaneous), Key Geographical Regions (North America, Europe, Asia-Pacific, and Rest of the World): Industry Trends and Global Forecasts, 2021-2031
... culminated in the USFDA's approval of LUMAKRAS™ (sotorasib) in 2021 for treating metastatic non ...
Biopharmaceutical Market Report by Indication (Autoimmune Diseases, Oncology, Metabolic Disorders, and Others), Class (Recombinant Proteins, Monoclonal Antibodies, Purified Proteins), and Region 2025-2033
... received FDA approval for Lumakras (sotorasib), a targeted therapy for non-small ...
Colorectal Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major colorectal cancer markets reached a value of US$ 13.6 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 17.3 Billion by 2034, exhibiting a growth rate (CAGR) of 2.22% during 2024-2034. The colorectal cancer market has ...
Cancer Immunotherapy Market Report by Therapy Type (Monoclonal Antibodies, Cancer Vaccines, Checkpoint Inhibitors, Immunomodulators, and Others), Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head and Neck Cancer, and Others), End User (Hospitals, Cancer Research Centers, Clinics, and Others), and Region 2024-2032
... , the US FDA approved Amgen's LUMAKRAS (Sotorasib) for the treatment of patients with ...
Global KRAS Inhibitor Market Research Report 2024, Forecast to 2032
... to the development of specific inhibitors, such as sotorasib and adagrasib, which target the ...
Global KRAS Inhibitor Market Growth 2024-2030
... to the development of specific inhibitors, such as sotorasib and adagrasib, which target the ...
United States Cancer Therapeutics Market Assessment, By Applications [Lung Cancer, Blood Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Glioblastoma, Head & Neck Cancer, Malignant Meningioma, Mesothelioma, Melanoma, Others], By Therapeutics [Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Other], By Top Selling Drugs [Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Temodar, Others], By End-user [Hospitals, Specialty Clinics, Cancer & Radiation Therapy Centers], By Region, Opportunities and Forecast, 2016-2030F
... Administration (US FDA) authorized Amgen's LUMAKRAS (sotorasib) In May 2021, approval was granted ...
Global KRAS Inhibitor Market Research Report 2025(Status and Outlook)
... to the development of specific inhibitors, such as sotorasib and adagrasib, which target the ...
Cancer Immunotherapy Market Size, Share, Trends and Forecast by Therapy Type, Application, End User, and Region, 2025-2033
... , the US FDA approved Amgen's LUMAKRAS (Sotorasib) for the treatment of patients with ...
|
|
|
|
